DiaMonTech selected as one of Europe's best deep tech scaleups at the EIT Digital Challenge 2019

Berlin, 7 October 2019

DiaMonTech GmbH, a young and innovative medical technology company has been nominated by EIT Digital, a leading European player in innovation and entrepreneurial education, as a finalist in its pan-European competition EIT Digital Challenge 2019. The competition focuses on startups in growth stage, so called scaleups, with deep tech products that leverage sophisticated, hard-to-reproduce technologies fueling the digital transformation.

"After winning the 'Start me up!' founder prize by BILANZ magazine in 2017, this is already the second renowned competition in which we have reached the final. In a field of nearly 300 participating start-ups, this is already a great distinction that gives us further impetus. With our ground-breaking method for non-invasive blood glucose monitoring, we are developing a product that many people have been waiting for," says Thorsten Lubinski, co-founder and CEO of DiaMonTech GmbH.

The participating companies from 12 European countries applied in five categories, strategically chosen with respect to major digital trends and European leadership potential: Digital Tech, Digital Industry, Digital Cities, Digital Finance and Digital Wellbeing. The finalists present their technology to an international expert jury of corporates and investors at the final event in Brussels on 6 November 2019.

About DiaMonTech

Founded in Berlin, Germany, in 2015, DiaMonTech is a medical technology company committed to improving health outcomes for people with diabetes and empowering them to take control of their lifelong health. Its pioneered and patented non-invasive “no prick” photothermal detection technology is fast and painless and doesn’t require needles or test strips. An industry first, DiaMonTech monitors the actual glucose molecules in skin, providing users with a more comprehensive and accurate reading comparable to invasive commercial devices. DiaMonTech achieved 99.1% accuracy in a test study with 100 people studied, received the CE mark as a medical device in April 2019 and is currently under FDA review. To support its mission, DiaMonTech is led by a world-class team of scientists, researchers and healthcare experts. 

More information about DiaMonTech can be found at www.diamontech.de.

Press contact
Markus Teuber
E-mail: hello@diamontech.de

The future begins now!

Stay tuned and get updates.

We are working hard in our lab day and night but it takes some time to develop a new medical device. Subscribe to our newsletter to get the latest news.

Notify me
Press
news@diamontech.de
INQUIRIES
hello@diamontech.de
Investor relations
ir@diamontech.de